Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Anixa Biosciences Inc
CY71Current price
3.32 EUR
+0.16 EUR (+5.06%)
Last closed
3.25 USD
Company
www.anixa.com
ISIN
US03528H1095
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
110 697 480 USD
Yield for 12 month
+8.68 %
1Y
3Y
5Y
10Y
15Y
CY71
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Address: 3150 Almaden Expressway, San Jose, CA, United States, 95118
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
8.5 USDP/E ratio
–Dividend Yield
–Current Year
+210 000 USD
Last Year
+2 469 000 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+49 000 USD
Last Year
+2 468 958 000 USD
Current Quarter
-3 000 USD
Last Quarter
-12 000 USD
Key Figures CY71
1 year
3 years
5 years
10 years
EBITDA
-13 097 416 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-34.65 %
PEG Ratio
–
Return On Equity TTM
-55.24 %
Wall Street Target Price
8.5 USD
Revenue TTM
–
Book Value
0.68 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
127 498 USD
Earnings per share
-0.39 USD
Diluted Eps TTM
-0.39 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CY71
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CY71
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:25
Payout Ratio
–
Last Split Date
26.06.2015
Dividend Date
–
Stock Valuation CY71
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
368.9827
Price Sales TTM
481.5351
Enterprise Value EBITDA
-8.7565
Price Book MRQ
5.0846
Financials CY71
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CY71
For 52 weeks
2.15 USD
5.13 USD
50 Day MA
3.28 USD
Shares Short Prior Month
627 222
200 Day MA
3.19 USD
Short Ratio
12.35
Shares Short
593 721
Short Percent
3.07 %
BeatStart